Immunoglobulin E (IgE) is a class of antibody distinguished by its epsilon heavy chains and its ability to bind tightly to receptors on mast cells and basophils. It is normally present at much lower concentrations in blood than other major antibody classes, yet it can produce powerful biological effects because much of its activity occurs while attached to cells in tissues. IgE is central to many forms of allergy, including reactions to pollen, animal allergens, foods, and insect venoms. It also participates in immune responses to parasitic worms.
IgE connects the specificity of adaptive immunity with rapid cellular responses involving histamine, lipid mediators, and inflammatory proteins. Its biological significance therefore depends less on its abundance in circulation than on where it is produced, which antigens it recognizes, and how it engages cellular receptors. Its discovery established the molecular basis of immediate allergic hypersensitivity; subsequent research has clarified its structure, production, receptor signaling, diagnostic significance, and value as a therapeutic target.
Discovery, classification, and distribution
The existence of a transferable blood factor responsible for immediate allergy was demonstrated before its molecular identity was known. In 1921, Carl Prausnitz and Heinz Küstner reported that serum from a person allergic to fish could transfer local skin sensitivity to another individual. The resulting reaction showed that a circulating substance could confer allergen-specific responsiveness on tissue. This activity was historically called “reagin,” a functional designation rather than the name of a defined antibody class. The serum-transfer procedure later became obsolete because it could transmit infections.
IgE was identified through converging investigations in the 1960s. Kimishige Ishizaka and Teruko Ishizaka, working with colleagues in Denver, associated reaginic activity with an immunoglobulin distinct from the recognized classes. Their key findings were published in 1966. Independently, S. Gunnar O. Johansson and Hans Bennich in Sweden characterized an unusual myeloma protein, initially called IgND. Comparison established that this protein and the antibody associated with reaginic activity belonged to the same class. The designation immunoglobulin E was internationally accepted in 1968. These findings transformed allergy from a phenomenon defined largely by physiological tests into one that could be investigated through a specific molecular component.
IgE is one of the five major human immunoglobulin classes, together with IgM, IgD, IgG, and IgA. These classes can share antigen-binding specificity while differing in their heavy-chain constant regions and biological functions. Unlike IgG, IgE does not undergo substantial receptor-mediated transfer across the placenta. It is also not a major antibody of mucosal secretions in the way secretory IgA is, although local IgE production and IgE-dependent responses can occur at mucosal surfaces.
Circulating IgE is typically measured in nanograms per milliliter or international units per milliliter, rather than the milligram-per-milliliter concentrations characteristic of IgG. The conventional conversion is approximately . Concentrations vary substantially with age, environmental exposure, infection, and allergic disease, so a single universal normal range is inappropriate. Free IgE has a serum half-life of approximately two to three days. Receptor-bound IgE can persist much longer, allowing tissues to remain sensitized after the concentration of free antibody has fallen. This distinction explains why serum measurements provide only a partial view of IgE biology: a small circulating pool can coexist with a functionally important reservoir on cells in the skin, respiratory tract, and gastrointestinal tract.
Molecular structure and antigen recognition
IgE is a glycosylated protein with an approximate molecular mass of 190 kilodaltons. Like other conventional antibodies, it contains two identical heavy chains and two identical light chains connected by disulfide bonds. Each heavy chain has a variable domain followed by four constant domains, designated through . The light chains are either kappa or lambda. The paired variable domains of a heavy and light chain form each of the molecule’s two antigen-binding sites, enabling recognition of a particular epitope on an antigen.
A major distinction from IgG is that IgE lacks the conventional flexible hinge separating the antigen-binding arms from the Fc region. Instead, an additional pair of constant domains, , contributes to the architecture between these regions. The IgE Fc portion adopts a markedly bent and conformationally dynamic structure rather than a simple extended arrangement. Structural studies using X-ray crystallography and other biophysical methods have shown that receptor binding involves conformational changes and asymmetry between the two heavy chains. These properties help explain both the tight binding to its high-affinity receptor and the ability of different therapeutic antibodies to interfere with receptor engagement.
IgE carries multiple carbohydrate attachments. Human epsilon chains contain seven potential sites for N-linked glycosylation, and the attached glycans contribute appreciably to molecular mass and behavior. Glycosylation is not merely decorative: a conserved glycan associated with the region is important for maintaining receptor-binding competence. Changes in glycan composition can influence molecular interactions, although not every observed glycosylation difference has a proven clinical consequence. The effects of glycosylation must therefore be distinguished from the much better established effects of antigen specificity and receptor occupancy.
The antigen-binding and receptor-binding functions occupy different parts of the molecule. The Fab arms recognize antigen, while the Fc region binds IgE receptors. This separation allows a mast cell coated with many IgE molecules to acquire a diverse repertoire of antigen recognition without synthesizing those antibodies itself. Antigen recognition depends on the variable-region sequence generated during B-cell development and subsequently modified during immune responses; receptor binding depends predominantly on the epsilon constant region.
IgE does not efficiently activate the classical complement pathway, unlike some IgG subclasses and IgM. Its principal effector mechanism is instead the recruitment and activation of receptor-bearing cells. This functional specialization illustrates why antibody class matters independently of specificity: two antibodies recognizing the same antigen can produce very different biological outcomes if one is IgE and the other is IgG.
Production, class switching, and immunological memory
IgE is produced by differentiated B cells, particularly plasma cells, after a regulated change in antibody heavy-chain expression. The initial antigen-binding repertoire is established through V(D)J recombination, which assembles variable-region gene segments. A B cell that initially expresses IgM and IgD can subsequently undergo class-switch recombination to place the same rearranged variable region next to the epsilon constant-region gene. Switching therefore changes the antibody’s effector class without, by itself, changing the antigen it recognizes.
In conventional T-cell-dependent responses, IgE switching requires coordinated signals rather than exposure to antigen alone. Interaction between CD40 on B cells and CD40 ligand on activated T cells provides an important contact-dependent signal. Interleukin-4 activates the STAT6 signaling pathway and promotes transcription through the epsilon switch region, making that region accessible to the switching machinery. Interleukin-13 can also support human IgE production under appropriate conditions. Activation-induced cytidine deaminase initiates DNA lesions in immunoglobulin switch regions; subsequent processing and joining connect the selected variable-region gene to the epsilon constant-region exons. The intervening DNA is generally excised, making the underlying rearrangement irreversible in that cell.
Switching can occur directly from IgM to IgE or sequentially through an intermediate class, particularly IgG. The relative contribution of these routes varies with species and immune context. Sequential switching can allow a clone that has already undergone somatic hypermutation and selection to generate high-affinity IgE. Within the germinal center, mutation and selection refine antigen binding through affinity maturation. IgE-expressing B cells show distinctive signaling and differentiation tendencies, including a strong propensity in many experimental settings to become antibody-secreting cells rather than persist as a large conventional memory-cell pool.
Persistent IgE responses do not depend simply on large numbers of circulating IgE-positive memory B cells. Long-lived plasma cells can maintain antibody production, and memory cells of another class can generate IgE-producing descendants after renewed stimulation. These mechanisms help explain why allergic responsiveness may persist for years despite the short serum half-life of free IgE. The precise balance between long-lived secretion and replenishment differs among allergens and individuals.
IgE production is restrained by several regulatory mechanisms. Regulatory T cells, inhibitory receptor signaling, and cytokines associated with immune tolerance can limit the development of type 2 responses. Conversely, epithelial signals generated by barrier injury can favor the cellular environment in which IgE switching occurs. These influences regulate the probability and magnitude of an IgE response; they do not mean that every antigen encountered at a damaged barrier necessarily induces IgE.
IgE receptors and cellular signaling
The principal high-affinity IgE receptor is FcεRI. On human mast cells and basophils, it usually consists of an IgE-binding alpha chain, a beta chain, and two disulfide-linked gamma chains. The beta and gamma components participate in intracellular signaling. Some human antigen-presenting cells express a trimeric form containing the alpha chain and two gamma chains but lacking beta. This variation allows IgE binding to serve different functions in different cellular settings, from rapid mediator release to antigen capture and presentation.
FcεRI binds the Fc portion of IgE with very high affinity, with an equilibrium dissociation constant on the order of , depending on experimental conditions. IgE can therefore occupy receptors even when its concentration in extracellular fluid is low. Binding also stabilizes receptor expression at the cell surface. As circulating IgE increases, receptor density can increase; when free IgE is substantially reduced, surface receptor expression commonly declines. Receptor occupancy alone is generally not equivalent to the strong activation produced when an antigen brings multiple receptor-bound IgE molecules together.
The central activating event is receptor aggregation. A multivalent allergen, or an antigen displaying repeated epitopes, can cross-link IgE molecules attached to neighboring FcεRI complexes. This promotes phosphorylation of immunoreceptor tyrosine-based activation motifs and recruitment of signaling proteins, notably the kinase Syk. Downstream pathways activate phospholipase C, generate intracellular second messengers, and increase cytosolic calcium through release from intracellular stores and entry across the cell membrane. Calcium-dependent processes and additional signaling pathways drive granule fusion, lipid-mediator synthesis, and changes in gene expression.
The consequences occur on different timescales. Preformed granule contents, including histamine and proteases, can be released within seconds to minutes. Newly generated lipid mediators, such as prostaglandin D₂ and cysteinyl leukotrienes, contribute to bronchoconstriction, vascular permeability, and cellular recruitment. Later production of cytokines and chemokines can sustain inflammation for hours or longer. The magnitude of the response depends on antigen dose and geometry, IgE affinity, receptor density, and activating or inhibitory signals from other receptors.
The second major receptor is CD23, also called FcεRII. It is a structurally unrelated, lower-affinity receptor with a C-type lectin-like domain and is expressed on B cells and several other cell types. Membrane-bound and soluble forms participate in IgE regulation, antigen handling, and interactions between immune cells. CD23 does not simply reproduce FcεRI signaling at lower sensitivity: its functions depend on cellular context, molecular assembly, and cleavage into soluble fragments.
Host defense, barrier tissues, and evolutionary context
IgE is characteristic of mammals and operates within immune pathways commonly described as type 2 immunity. These pathways coordinate responses involving mast cells, basophils, eosinophils, mucus production, smooth-muscle activity, and tissue repair. Their best-established infectious context is exposure to parasitic worms. Large multicellular parasites cannot be eliminated by the same mechanisms used to engulf many bacteria, so protective responses often act by damaging parasite surfaces, restricting development, or changing the tissue environment in ways that reduce survival and promote expulsion.
Parasite-specific IgE can coat larvae or parasite-derived antigens and engage receptor-bearing effector cells. Mast-cell mediators increase intestinal fluid secretion, vascular permeability, and smooth-muscle contraction. In experimental infections, these responses can help dislodge worms or alter their access to host tissues. Eosinophils can release granule proteins and other mediators near parasites, but their contribution varies markedly among parasite species and stages. Human eosinophil expression of functional IgE receptors is also context-dependent, so eosinophil activity should not be treated as uniformly IgE-driven.
Human epidemiological studies have associated parasite-specific IgE with resistance to reinfection in some helminth infections, including schistosomiasis. Such associations do not establish that IgE alone provides protection. Age, exposure intensity, prior treatment, other antibody classes, and cellular responses all influence infection outcomes. Experimental studies likewise show that IgE can be important in some host–parasite combinations but dispensable in others. High total IgE during a worm infection is therefore evidence of immune activation, not a direct measurement of effective protection.
IgE-dependent responses are particularly well positioned at barriers. Mast cells reside near blood vessels, nerves, and epithelial surfaces, allowing them to alter local circulation, secretion, sensation, and muscle activity. This arrangement can produce rapid defensive changes before a large number of immune cells arrives. The same anatomical positioning also explains why inappropriate activation produces prominent skin, respiratory, and gastrointestinal symptoms. Defensive function and allergic pathology use much of the same cellular machinery; the difference lies partly in the target and circumstances of activation.
An additional line of research concerns responses to venoms and other tissue-damaging substances. Animal experiments have shown that IgE-dependent responses can improve resistance to certain venom exposures, and mast-cell proteases can degrade some toxic components. These results support a possible protective role for allergic-type mechanisms under particular conditions, but they do not establish that human venom allergy is beneficial. The evolutionary explanation for IgE is consequently broader than a single-purpose anti-parasite model, while the relative importance of different selective pressures remains an active research question.
Sensitization and immediate allergic disease
An IgE-mediated allergic response usually involves sensitization followed by an elicitation phase. During sensitization, antigen exposure leads to production of allergen-specific IgE, which binds FcεRI on tissue mast cells and blood basophils. Sensitization may occur without recognized symptoms. On a later exposure, sufficiently effective cross-linking of cell-bound IgE can trigger mediator release. The distinction between sensitization and clinical allergy is fundamental: a detectable antibody response demonstrates immune recognition, whereas disease requires a relevant physiological reaction under actual exposure conditions.
The site and route of exposure strongly influence the clinical pattern. In the nose, mediator release can cause sneezing, itching, secretion, and congestion. In the lower airways it can contribute to bronchoconstriction and features of allergic asthma. In the skin, increased vascular permeability produces the wheal-and-flare response used in allergy testing. Food allergens may provoke gastrointestinal symptoms, skin symptoms, respiratory involvement, or systemic reactions. Similar cellular mechanisms can therefore generate different syndromes because the activated cells occupy different tissues.
The immediate response commonly develops within minutes, while a late-phase response can emerge several hours later. Late responses involve recruitment of eosinophils, T cells, and other inflammatory cells, together with continued mediator production. Repeated exposure can maintain inflammation and contribute to altered tissue function. IgE is nevertheless not the sole mechanism in diseases commonly associated with allergy. Asthma has allergic and nonallergic forms, and atopic dermatitis involves barrier dysfunction and multiple immune pathways even when total IgE is elevated.
Anaphylaxis is a rapidly developing systemic hypersensitivity reaction that can involve the respiratory and cardiovascular systems as well as the skin and gastrointestinal tract. IgE-mediated activation is an important mechanism, especially in reactions to foods, venoms, and some medications. Widespread mediator release can produce vascular leakage, reduced vascular tone, bronchoconstriction, and mucosal swelling. However, not every episode of anaphylaxis is IgE-mediated, and the clinical syndrome cannot be defined solely by an antibody test.
Allergen recognition is also affected by molecular relationships between substances. IgE directed against one protein may bind a structurally similar protein from another source. This cross-reactivity helps explain some associations between pollen sensitization and reactions to plant foods. Cross-reactive carbohydrate structures can generate positive laboratory results with limited clinical significance. Allergen affinity, epitope accessibility, resistance to digestion, exposure dose, and other physiological conditions influence whether recognition progresses to symptoms. Neither a positive result nor a high antibody concentration alone provides a universal measure of reaction severity.
Laboratory measurement and clinical interpretation
Total IgE assays measure the combined concentration of circulating IgE regardless of antigen specificity. Modern methods generally use antibody-based immunoassays calibrated against international reference preparations. Laboratories commonly report results in , numerically equivalent to . Reference intervals depend strongly on age and also vary with the population and analytical method. Total IgE can be elevated in allergic disease, parasitic infection, certain immunodeficiencies, and other conditions, but it can also fall within the reference interval in a person with clinically important IgE-mediated allergy.
Allergen-specific IgE assays measure binding to an allergen extract or a defined molecular component. Extract-based assays contain mixtures of proteins and sometimes other antigenic material from a source such as grass pollen, peanut, or house-dust mite. Component-resolved testing instead assesses selected purified or recombinant molecules. This can distinguish recognition of a source-associated protein from recognition of a widely shared cross-reactive protein. For example, IgE to particular storage proteins may carry a different clinical association from IgE to a pollen-related protein in the same food. These associations remain probabilistic rather than absolute.
Historically, the radioallergosorbent test, or RAST, used radiolabeled reagents to detect allergen-specific IgE. Most contemporary laboratory platforms use nonradioactive detection, although “RAST” sometimes persists as an imprecise generic name. A commonly used historical reporting threshold is , while modern assays may quantify lower concentrations. A reporting threshold is not a universal boundary separating allergy from health. The predictive meaning of a value depends on the allergen, assay, age group, exposure history, and prevalence of disease in the tested population.
Skin-prick testing evaluates a related but distinct phenomenon: the ability of an applied allergen to induce an immediate local response through IgE-bearing cells in skin. It measures tissue responsiveness rather than serum antibody directly. Medication effects, skin condition, reagent quality, and technique can influence results. Basophil activation tests provide another functional approach, using flow cytometry to detect activation markers after blood basophils encounter an allergen. These tests can add information in selected settings, but their performance depends on laboratory procedures and the responsiveness of the sampled cells.
Laboratory results are interpreted within the broader process of diagnosis. Controlled allergen exposure, such as a medically supervised food challenge, can assess whether sensitization corresponds to clinical reactivity when the relationship remains uncertain. Specialized testing also requires attention to treatment effects: conventional total-IgE assays can detect IgE contained in complexes with anti-IgE medication, producing an increased measured total even while biologically available free IgE has fallen. Serum concentration, receptor-bound antibody, cellular activation, and symptoms are therefore related measurements, not interchangeable ones.
Elevated IgE, immune disorders, and atypical presentations
Markedly elevated IgE is not a diagnosis in itself. Severe atopic dermatitis can produce very high concentrations, sometimes reaching thousands of international units per milliliter. Helminth infections may also drive substantial polyclonal IgE production, especially when the parasite interacts with tissues. These increases differ from a narrowly focused response to a single allergen. Their interpretation depends on accompanying clinical findings and other immune measurements, rather than on the magnitude of total IgE alone.
Hyper-IgE syndromes comprise genetically distinct disorders in which elevated IgE occurs alongside characteristic infectious and noninfectious manifestations. The classical autosomal dominant form is most often caused by dominant-negative variants in STAT3 and is associated with eczema, recurrent skin and pulmonary infections, and skeletal or connective-tissue abnormalities. Impaired development of interleukin-17-producing helper T cells contributes to susceptibility to particular infections. The name emphasizes a conspicuous laboratory feature, but high IgE does not account for the full disease mechanism.
Other inherited immune disorders can produce a superficially similar laboratory pattern through different pathways. Biallelic DOCK8 deficiency is a combined immunodeficiency associated with severe viral skin infections, eczema, and prominent allergic manifestations. Its biology involves defects in immune-cell function rather than the STAT3 mechanism. Additional disorders affecting immune regulation or barrier function may also cause elevated IgE. Grouping all such conditions together solely because of the antibody concentration obscures clinically important genetic and mechanistic differences.
In allergic bronchopulmonary aspergillosis, immune responses to Aspergillus growing within airway mucus contribute to a complex inflammatory disease, most often in people with asthma or cystic fibrosis. Elevated total IgE and fungus-specific IgE are important laboratory features, alongside other immunological, clinical, and imaging findings. IgE measurements can also help track disease activity, although concentrations are affected by treatment and must be interpreted with the rest of the assessment. This condition illustrates how microbial exposure can produce pathology dominated by hypersensitivity rather than by invasive infection.
Rarely, a plasma-cell neoplasm produces a monoclonal IgE protein. IgE myeloma is an exceptionally uncommon form of multiple myeloma and is biologically distinct from the polyclonal IgE elevation typical of allergy. At the opposite extreme, very low or undetectable IgE can occur in healthy individuals as well as in some antibody deficiencies. A universally accepted, stand-alone disease category defined only by absent IgE has not been established. Neither extreme of concentration can be assigned a single cause without examining the broader immune and clinical context.
Therapeutic targeting and experimental directions
IgE is an attractive therapeutic target because it lies upstream of several effector mechanisms in immediate allergy. The best-established direct approach uses omalizumab, a humanized monoclonal antibody that binds free IgE at a region overlapping its FcεRI-binding interface. It prevents additional IgE from occupying the high-affinity receptor and does not cross-link FcεRI-bound IgE. As free IgE falls, receptor expression on basophils and other responsive cells decreases over time, reducing their sensitivity to allergen stimulation.
The biological effects are not equivalent to instant removal of all IgE from tissues. Existing receptor-bound antibody must dissociate or be lost through receptor and cell turnover. Moreover, IgE–drug complexes can persist in circulation and increase the total IgE detected by routine assays. This pharmacology explains why free-IgE suppression, total-IgE concentration, receptor density, and clinical response can follow different time courses. It also distinguishes IgE neutralization from direct inhibition of histamine receptors or other downstream mediators.
Omalizumab first received United States approval for allergic asthma in 2003, with additional indications added subsequently. In 2024, the United States Food and Drug Administration approved it for reducing allergic reactions, including anaphylaxis, resulting from accidental exposure to one or more foods in eligible patients aged one year and older with IgE-mediated food allergy. Its approved use does not make it an emergency treatment for anaphylaxis or establish that unrestricted exposure is safe. Approvals for other conditions, including chronic spontaneous urticaria and chronic rhinosinusitis with nasal polyps, reflect the involvement of IgE-related pathways beyond straightforward reactions to an external allergen.
Allergen immunotherapy acts differently. Repeated administration of defined allergen preparations can alter immune responsiveness through changes in regulatory pathways, effector-cell sensitivity, and antibody production. Allergen-specific IgG, often including IgG4, can interfere with allergen access to IgE and with IgE-facilitated antigen presentation. Allergen-specific IgE may initially rise and later decline, but its concentration alone does not adequately measure the treatment’s effects. Oral immunotherapy for food allergy likewise can raise reaction thresholds without necessarily producing permanent, exposure-independent tolerance.
Other therapies affect IgE indirectly by blocking signals that support type 2 immunity. Dupilumab blocks the interleukin-4 receptor alpha chain shared by the IL-4 and IL-13 receptor systems and can reduce IgE production over time, while also affecting many processes unrelated to IgE. Experimental approaches include antibodies targeting different IgE epitopes, strategies directed at IgE-expressing B cells, and interventions in receptor signaling. A central research problem is the persistence of allergen-specific memory and antibody secretion: suppressing circulating free IgE is mechanistically different from eliminating the cellular sources capable of regenerating it.